
149 Bio LLC Profile last edited on: 3/11/2024
CAGE: 8J9F3
UEI: PUXSSH1GHNF7
Business Identifier: Developing Integrin Activators as First-In-Class Kidney Disease Therapeutics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 26
County: Miami-Dade
Congr. District: 26
County: Miami-Dade
Public Profile
149 Bio is a startup company developing breakthrough medicines to treat kidney diseases. Firm have developed a novel proprietary platform to identify and develop novel therapeutic candidates. Company's platform allows rapid discovery and determines their mechanism of action to rapid drug development.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 1 | NIH | $306,500 | |
Project Title: Integrin-Targeted Novel Oral Therapeutics for Lupus Nephritis |
Key People / Management
Vineet Gupta -- Founder, CEO
Santiago Balza -- Research Scientist
Antonio Barbosa -- Vice President Research
Darlah Michelle Lopez -- Staff Scientist
Santiago Balza -- Research Scientist
Antonio Barbosa -- Vice President Research
Darlah Michelle Lopez -- Staff Scientist
Company News
There are no news available.